Gene therapy for Parkinson's disease: An approach to the prevention or palliation of levodopa-associated motor complications

Experimental Neurology

Volumn 144, Issue 1, 1997, Pages 51-57

  Mouradian, M Maral ^a   Chase, Thomas N ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; NEUROPROTECTIVE AGENT; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; GENE THERAPY; HUMAN; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 0031105295     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1996.6388     Document Type: Article

References (65)

1. 1. AEBISHCER, P., P. A. TRESCO, J. SAGEN, AND S. R. WINN. 1991. Transplantation of microencapsulated bovine chromaffin cells reduces lesion-induced rotational asymmetry in rats. Brain Res. 560: 43-49.
2. 2. AEBISCHER, P., P. A. TRESCO, S. R. WINN, L. A. GREENE, AND C. B. JAEGER. 1991. Long-term cross-species brain transplantation of a polymer-encapsulated dopamine-secreting cell line. Exp. Neurol. 111: 269-275.
3. 3. ANTON, R., J. H. KORDOWER, N. T. MAIDMENT, J. S. MANASTER, D. J. KANE, S. RABIZADEH, S. B. SCHUELLER, J. YANG, S. RABIZADEH, R. H. EDWARDS, C. H. MARKHAM, AND D. E. BREDESEN. 1994. Neural-targeted gene therapy for rodent and primate hemiparkinsonism. Exp. Neurol. 127: 207-218.
4. 4. BANKIEWICZ, K., R. J. MANDEL, AND M. V. SOFRONIEW. 1993. Trophism, transplantation and animal models of Parkinson's disease. Exp. Neurol. 124: 140-149.
5. 5. BARONTI, F., M. M. MOURADIAN, T. L. DAVIS, M. GIUFFRA, G. BRUGHITTA, K. E. CONANT, AND T. N. CHASE. 1992. Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease. Ann. Neurol. 32: 776-781.
6. 6. BEDARD, P. J., B. G. MANCILLA, P. BLANCHETTE, C. GAGNON, AND T. DI PAOLO. 1992. Levodopa-induced dyskinesias: Facts and fancy. What does the MPTP monkey model tell us? Can. J. Neurol. Sci. 19: 134-137.
7. 7. BLANCHET, P. J., L. VERHAGEN METMAN, M. M. MOURADIAN, AND T. N. CHASE. 1996. Movement Disord. 11: 580-581.
8. 8. BOYCE, S., C. E. CLARKE, R. LUQUIN, D. PEGGS, R. G. ROBERTSON, I. J. MITCHELL, M. A. SAMBROOK, AND A. R. CROSSMAN. 1990. Induction of chorea and dystonia in parkinsonian primates. Movement Disord. 5: 3-7.
9. 9. BRAVI, D., M. M. MOURADIAN, J. W. ROBERTS, T. L. DAVIS, Y. H. SOHN, AND T. N. CHASE. 1994. Wearing-off fluctuations in Parkinson's disease: Contribution of postsynaptic mechanisms. Ann. Neurol. 36: 27-31.
10. 10. BULLER, A. L., H. C. LARSON, B. E. SCHNEIDER, J. A. BEATON, R. A. MORRISETT, AND D. T. MONAGHAN. 1994. The molecular basis of NMDA receptor subtypes: Native receptor diversity is predicted by subunit composition. J. Neurosci. 14: 5471-5484.
11. 11. CAO, L., Z.-C. ZHENG, Y.-C. ZHAO, Z.-H. JIANG, Z.-G. LIU, S.-D. CHEN, C.-F. ZHOU, AND X.-Y. LIU. 1995. Gene therapy of Parkinson disease model rat by direct injection of plasmid DNA-lipofectin. Hum. Gene Ther. 6: 1497-1501.
12. 12. CEPEDA, C., N. A. BUCHWALD, AND M. S. LEVINE. 1993. Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated. Proc. Natl. Acad. Sci. USA 90: 9576-9580.
13. 13. CHASE, T. N., F. BARONTI, G. FABBRINI, I. J. HEUSER, J. L. JUNCOS, AND M. M. MOURADIAN. 1989. Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Neurology 39(Suppl. 2): 7-10.
14. 14. CHASE, T. N., T. M. ENGBER, AND M. M. MOURADIAN. 1994. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease. Neurology 44: S15-18.
15. 15. CHASE, T. N., T. M. ENGBER, AND M. M. MOURADIAN. 1996. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. Adv. Neurol. 69: 497-501.
16. 16. CHASE, T. N., L. VERHAGEN, AND M. M. MOURADIAN. 1996. Striatal glutamatergic mechanisms and the pathogenesis of motor response complications. Movement Disord. 11(Suppl. 1): 10.
17. 17. DURING, M. J., J. R. NAEGELE, K. L. O'MALLEY, AND A. I. GELLER. 1994. Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science 266: 1399-1403.
18. 18. EMERICH, D. F., P. E. MCDERMOTT, P. M. KRUEGER, B. FRYDEL, P. R. SANBERG, AND S. R. WINN. 1993. Polymer-encapsulated PC12 cells promote recovery of motor function in aged rats. Exp. Neurol. 122: 37-17.
19. 19. ENGBER, T. M., Z. SUSEL, J. L. JUNCOS, AND T. N. CHASE. 1989. Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists. Eur. J. Pharmacol. 168: 291-298.
20. 20. ENGBER, T. M., Z. SUSEL, S. KUO, C. R. GERFEN, AND T. N. CHASE. 1991. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res. 552: 113-118.
21. 21. ENGBER, T. M., R. C. BOLDRY, S. KUO, AND T. N. CHASE. 1992. Dopaminergic modulation of striatal neuropeptides: Differential effects of D1 and D2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalin. Brain Res. 581: 261-268.
22. 22. ENGBER, T. M., S. M. PAPA, R. C. BOLDRY, AND T. N. CHASE. 1994. NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport 5: 2586-2588.
23. 23. FABBRINI, G., J. JUNCOS, M. M. MOURADIAN, C. SERRATI, AND T. N. CHASE. 1987. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann. Neurol. 21: 370-376.
24. 24. FABBRINI, G., M. M. MOURADIAN, J. L. JUNCOS, J. SCHLEGEL, E. MOHR, AND T. N. CHASE. 1988. Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, Part I. Ann. Neurol. 24: 366-371.
25. 25. FISHER, L. J., H. A. JINNAH, L. C. KALE, G. A. HIGGINS, AND F. H. GAGE. 1990. Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-DOPA. Neuron 6: 371-380.
26. 26. GAGE, F. H., M. B. ROSENBERG, M. H. TUSZYNSKI, K. YOSHIDA, D. M. ARMSTRONG, R. C. HAYES, AND T. FRIEDMANN. 1990. Gene therapy in the CNS: Intracerebral grafting of genetically modified cells. Prog. Brain Res. 86: 205-217.
27. 27. GERFEN, C. R., T. M. ENGBER, L. C. MAHAN, Z. SUSEL, T. N. CHASE, F. J. MONSMA JR., AND D. R. SIBLEY. 1990. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250: 1429-1432.
28. 28. GOETZ, C. G., G. T. STEBBINS III, H. L. KLAWANS, W. C. KOLLER, R. G. CROSSMAN, R. A. BAKAY, AND R. D. PENN. 1990. United Parkinson Foundation neurotransplantation registry: Multicenter U.S. and Canadian data base, presurgical and 12 month follow-up. Prog. Brain Res. 82: 611-617.
29. 29. HORELLOU, P., P. BRUNDIN, P. KALEN, J. MALLET, AND A. BJORKLUD. 1990. In vivo release of DOPA and dopamine from genetically engineered cells grafted to the denervated rat striatum. Neuron 5: 393-402.
30. 30. HORELLOU, P., L. MARLIER, A. PRIVAT, AND J. MALLET. 1990. Behavioral effect of engineered cells that synthesize L-DOPA or dopamine after grafting into the rat neostriatum. Eur. J. Neurosci. 2: 116-119.
31. 31. HUANG, C. C., AND P. W. GEAN. 1995. Cyclic adenosine-3′,5′-monophosphate potentiates the synaptic potential mediated by NMDA receptors in the amygdala. J. Neurosci. Res. 40: 747-754.
32. 32. JAEGER, C. B., P. AEBISCHER, P. A. TRESCO, S. R. WINN, AND L. A. GREENE. 1992. Growth of tumor cell lines in polymer capsules: Ultrastructure of encapsulated PC12 cells. J. Neurocytol. 21: 469-480.
33. 33. JAEGER, C. B., L. A. GREENE, P. A. TRESCO, S. R. WINN, AND P. AEBISCHER. 1990. Polymer encapsulated dopaminergic cell lines as alternative neural grafts. Prog. Brain Res. 82: 41-16.
34. 34. JINNAH, H. A., AND T. FRIEDMANN. 1995. Gene therapy and the brain. Br. Med. Bull. 51: 138-148.
35. 35. JUNCOS, J. L., T. M. ENGBER, R. RAISMAN, Z. SUSEL, F. THIBAUT, A. PLOSKA, Y AGID, AND T. N. CHASE. 1989. Continuous and intermittent levodopa differentially affect basal ganglia function. Ann. Neurol. 25: 473-178.
36. 36. KAPLITT, M. G., P. LEONE, R. J. SAMULSKI, X. XIAO, D. W PFAFF, K. L. O'MALLEY, AND M. J. DURING. 1994. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat. Genet. 8: 148-154.
37. 37. KARPATTI, G., H. LOCHMULLER, NALBANTOGLU, AND H. DURHAM. 1996. The principles of gene therapy for the nervous system. Trends Neurosci. 19: 49-54.
38. 38. KOTTER, R. 1994. Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum. Prog. Neurobiol. 44: 163-196.
39. 39. LINDNER, M. D., S. R. WINN, E. E. BAETGE, J. P. HAMMANG, F. T. GENTILE, E. DOHERTY, P. E. MCDERMOTT, B. FRYDEL, M. D. ULLMAN, T. SCHALLERT, AND D. F. EMERICH. 1995. Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms. Exp. Neurol. 132: 62-76.
40. 40. LINDVALL, O., P. BRUNDIN, H. WIDNER, S. REHNCRONA, B. GUSTAVII, R. FRACKOWIAK, K. L. LEENDERS, G. SAWLE, J. C. ROTHWELL, C. D. MARSDEN, ET AL. 1990. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 247: 574-577.
41. 41. MARSDEN, C. 1994. Problems with long-term levodopa therapy for Parkinson's disease. Clin. Neuropharmacol. 17: S32-S44.
42. 42. MARIN, C., S. M. PAPA, T. M. ENGBER, M. BONASTRE, E. TOLOSA, AND T. N. CHASE. 1996. MK801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res. 736: 202-205.
43. 43. MELAMED, E., F. HEFTI, AND R. J. WURTMAN. 1980. Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism. Ann. Neurol. 8: 558-563.
44. 44. MOURADIAN, M. M., J. L. JUNCOS, G. FABBRINI, J. SCHLEGEL, J. J. BARTKO, AND T. N. CHASE. 1988. Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, Part II. Ann. Neurol. 24: 372-378.
45. 45. MOURADIAN, M. M., AND T. N. CHASE. 1988. Central mechanisms and levodopa response fluctuations in Parkinson's disease. Clin. Neuropharmacol. 11: 378-385.
46. 46. MOURADIAN, M. M., I. J. HEUSER, F. BARONTI, G. FABBRINI, J. L. JUNCOS, AND T. N. CHASE. 1988. Pathogenesis of dyskinesias in Parkinson's disease. Ann. Neurol. 25: 523-526.
47. 47. MOURADIAN, M. M., I. J. HEUSER, F. BARONTI, AND T. N. CHASE. 1990. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann. Neurol. 27: 18-23.
48. 48. PAPA, S. M., T. M. ENGBER, A. M. KASK, AND T. N. CHASE. 1994. Motor fluctuations in levodopa treated parkinsonian rats: Relation to lesion extent and treatment duration. Brain Res. 662: 69-74.
49. 49. PAPA, S. M., R. C. BOLDRY, T. N. ENGBER, A. KASK, AND T. N. CHASE. 1995. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res. 701: 13-18.
50. 50. PAPA, S. M., AND T. N. CHASE. 1996. Levodopa induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann. Neurol. 39: 574-578.
51. 51. PEPPE, A., J. M. DAMBROSIA, AND T. N. CHASE. 1993. Risk factors for motor response complications in L-dopa-treated parkinsonian patients. Adv. Neurol. 60: 698-702.
52. 52. RAYMOND, L. A., C. D. BLACKSTONE, AND R. L. HUGANIR. 1993. Phosphorylation and modulation of recombinant GluR6 glutamate receptors by cAMP-dependent protein kinase. Nature 361: 637-641.
53. 53. RIDET, J.-L., AND A. PRIVAT. 1995. Gene therapy in the central nervous system: Direct versus indirect gene delivery. J. Neurosci. Res. 42: 287-293.
54. 54. ROBERTS, J. W., G. CORA-LOCATELLI, D. BRAVI, M. A. AMANTEA, M. M. MOURADIAN, AND T. N. CHASE. 1993. Catechol-O-methyl-transferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 43: 2685-2688.
55. 55. SCHULTZ, W. 1994. Behavior-related activity of primate dopamine neurons. Rev. Neurol. (Paris) 150: 634-639.
56. 56. SHOULSON, I., G. A. GLAUBIGER, AND T. N. CHASE. 1975. On-off response: Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 25: 1144-1148.
57. 57. STANDAERT, D. G., C. M. TESTA, A. B. YOUNG, AND J. J. PENNEY. 1994. Organization of N-methyl-D-aspartate glutamate receptor gene expression in the basal ganglia of the rat. J. Comp. Neurol. 343: 1-16.
58. 58. SUHR, S. T., AND F. H. GAGE. 1993. Gene therapy for neurologic disease. Arch. Neurol. 50: 1252-1268.
59. 59. TRESCO, P. A., S. R. WINN, S. TAN, C. B. JAEGER, L. A. GREENE, AND P. AEBISCHER. 1992. Polymer-encapsulated PC12 cells: Long-term survival and associated reduction in lesion-induced rotational behavior. Cell Transplant. 1: 255-264.
60. 60. THOMAS, K. L., S. DAVIS, S. LAROCHE, AND S. P. HUNT. 1994. Regulation of the expression of NR1 NMDA glutamate receptor subunits during hippocampal LTP. Neuroreport 6: 119-123.
61. 61. VERHAGEN-METMAN, L., E. R. LOCATELLI, D. BRAVI, M. M. MOURADIAN, AND T. N. CHASE. Apomorphine responses in Parkinson's disease and the pathogenesis of motor response complications. Neurology, in press.
62. 62. VERHAGEN METMAN, L., P. J. BLANCHET, M. M. MOURADIAN, AND T. N. CHASE. 1996. Dextromethorphan and levodopa combination therapy in parkinsonian patients with response fluctuations. Movement Disord. 11(Suppl 1): 184.
63. 63. WINN, S. R., P. A. TRESCO, B. ZIELINSKI, L. A. GREENE, C. JAEGER, AND P. AEBISCHER. 1991. Behavioral recovery following intrastriatal implantation of microencapsulated PC12 cells. Exp. Neurol. 113: 322-329.
64. 64. WINN, S. R., L. WAHLBERG, P. A. TRESCO, AND P. AEBISCHER. 1989. An encapsulated dopamine-releasing polymer alleviates experimental parkinsonism in rats. Exp. Neurol. 105: 244-250.
65. 65. YUSTE, R., AND D. W. TANK. 1996. Dendritic integration in mammalian neurons, a century after Cajal. Neuron 16: 701-716.